Listen to the article
FDA Introduces Performance Bonuses for Drug Reviewers Amid Agency Overhaul
FDA Commissioner Marty Makary announced plans Thursday to implement a pilot program offering bonus payments to agency drug reviewers who complete their work ahead of schedule. The initiative, described during a staff presentation obtained by The Associated Press, would begin quarterly payments to eligible employees starting around August.
“My job as your commissioner is to be your advocate and to fight for you,” Makary told FDA staffers, noting that securing approval for the payments required “some wrangling.” He added candidly, “If you don’t like it, we can get rid of it, but usually everybody loves money.”
The unprecedented bonus system raises significant questions about implementation and potential consequences. The plan will base payments on “weighted time savings” achieved by employees and their teams, along with ratings for “work quality and work complexity.” However, it remains unclear exactly how these payments will be distributed across the large teams typically involved in drug reviews. Only employees directly engaged in drug reviews will be eligible, excluding other agency workers such as factory inspectors.
Since the 1990s, the FDA has collected fees from pharmaceutical companies to fund staff positions dedicated to expediting reviews of new prescription drugs and vaccines. Under agreements with industry, the agency follows established timelines and metrics for completing reviews. However, until now, the FDA has never directly compensated workers for meeting or exceeding these goals.
According to presentation slides, the bonus program aims “to recognize and reward staff who find ways to be more efficient delivering high-quality work activities that ultimately benefit patients.” Agency officials emphasized that while the program values speed, it would never sacrifice quality.
The initiative comes at a critical time for the FDA, which has experienced significant workforce reductions. Agency records show that the drug and biologics centers—responsible for overseeing prescription drugs, vaccines, and biotech drugs—have lost approximately 20% of their employees since President Donald Trump took office a year ago. The agency also faces challenges with some reviewers being unable to work on certain projects because they are actively interviewing for positions in the pharmaceutical industry.
Critics worry the bonus system could harm public perception of the FDA, an agency already scrutinized for its relationship with the pharmaceutical industry it regulates. Health Secretary Robert F. Kennedy Jr., who oversees the agency, has been particularly critical, describing FDA staffers as “a sock puppet” of industry since his appointment last February.
The pharmaceutical industry currently finances about 70% of the FDA’s drug program through user-fee payments when companies submit products for review. This arrangement has enabled the agency to hire thousands of additional scientists and reduce review times by more than half compared to the era before such funding.
Since joining the FDA in April, Makary has launched several initiatives aimed at expediting the agency’s review processes. These include offering one-month drug assessments for new medications serving “national interests,” abandoning the longtime standard requiring two clinical trials for drug reviews, and creating a new pathway for therapies that can only be tested in small patient populations.
These changes promoting faster, streamlined approvals occur against a backdrop of criticism regarding the FDA’s handling of vaccines, gene therapies, and other specialty treatments. Dr. Vinay Prasad, the FDA’s chief scientist and vaccine director, has recently overruled staff in rejecting several experimental therapies and biotech drugs, citing the need for additional studies and more conclusive evidence.
A recent case highlighting the agency’s evolving approach involved Moderna’s application for a new mRNA flu shot. Prasad initially rejected the application, deeming the clinical trial insufficient. However, less than a week later, the FDA reversed course and agreed to review the vaccine after Moderna committed to conducting an additional study in older populations.
Industry observers note that these rapid policy changes represent one of the most significant overhauls in FDA history, with potentially far-reaching implications for drug development timelines and safety protocols in the United States.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
9 Comments
This bonus program could potentially help the FDA clear its backlog of drug applications more quickly. However, I’m a bit skeptical about the potential for cutting corners or compromising on safety standards. Curious to see how it unfolds.
Valid concern. The FDA will need robust oversight to ensure the program maintains high quality standards while delivering timely approvals.
This seems like a creative approach to address the FDA’s well-known challenges with drug review backlogs. However, I worry that bonuses could create perverse incentives and undermine the thorough, impartial evaluation process. Rigorous oversight will be critical.
That’s a valid concern. The FDA will need to design the bonus program very carefully to maintain its high standards of scientific review and patient safety.
Interesting move by the FDA to incentivize quicker drug reviews. I wonder if this could lead to any unintended consequences around quality control or work-life balance for staff. It will be important to monitor the program’s impacts closely.
You raise a good point. Balancing speed and quality is crucial for drug approvals. Hopefully the FDA has safeguards in place to ensure reviews remain thorough.
As someone invested in the biotech sector, I’m cautiously optimistic about this incentive program for FDA reviewers. Faster drug approvals could mean quicker access to new treatments for patients. But regulatory integrity must remain the top priority.
I agree, the patient impact is an important consideration. Hopefully the FDA can strike the right balance between efficiency and safety with this new initiative.
As a shareholder in several biotech companies, I’m hopeful this initiative could help accelerate access to innovative new drugs. But I also share the concerns about potential quality control issues. The FDA must ensure the integrity of its review process.